AUG 14, 2018 11:40 PM PDT

Using Arsenic to Enhance Cancer Therapies Beyond Leukemia

WRITTEN BY: Mauri Brueggeman

Arsenic is anecdotally known to many as a poison, but it has historically been a potent chemotherapy agent.  Chemotherapies are basically controlled poisons; it is not so far-fetched to think of arsenic in these terms.  Originally used to treat leukemia in the nineteenth century, known as Fowler’s solution, arsenic continues to be investigated and used in conjunction with all-trans retinoic acid (ATRA) for the treatment and cure of Acute Promyelocytic Leukemia (APL).  Specifically, arsenic trioxide (ATO) is the active component needed to promote the anti-leukemic process in the body.  ATO acts on APL by destroying the main fusion protein called PML-RARα which is the disease driving genetic change causing the arrest of myelocytic cell differentiation.  Myelocytic cells need retinoic acid, or vitamin A, to continue developing into mature neutrophils which is why ATRA was used in the first place. 

A recent study published in Nature Communications outlines how ATO and ATRA together target an oncogenic signaling regulator called Pin1.  Pin1 activity is documented in multiple cancers besides leukemia including breast and liver solid tumors.  ATO has been found to degrade Pin1 and ATRA controls the cell’s ability to take up ATO when it is in the body.    

This is an emerging area of research because solid tumors are challenging to target; tumors are often found to utilize multiple activation pathways to remain viable and support their rapid growth.  Blocking one pathway may not work but finding the target that drives a multitude of signaling mechanisms, like in the case of Pin1, provides promise.  ATO and ATRA together have been proven safe at clinical doses and inhibited triple negative breast cancer cells as well as other tumor initiating cells in animal models. 

In vivo studies and clinically relevant data have demonstrated the viability and efficacy of using arsenic in conjunction with other therapeutic agents, like in the case of ATO-ATRA and APL.  Because this combination was found to impede further tumor growth via tumor initiating cells, the tumor’s normal renewal and progression process is disrupted.  In fact, the authors found that Pin1 is “highly enriched” in breast tumor initiating cells and propose further study on whether Pin1 inhibitor drugs could target these specific breast tumor cells.

Sources: Nature Communications, Pathology Outlines, Nature Medicine, Journals of Hematology & Oncology,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
SEP 13, 2020
Cancer
Should we be treating kidney cancer differently?
SEP 13, 2020
Should we be treating kidney cancer differently?
New research published in the journal Clinical Cancer Research is questioning how we treat kidney tumors. According ...
SEP 23, 2020
Cancer
Can Increased Pain Indicate Oral Cancer?
SEP 23, 2020
Can Increased Pain Indicate Oral Cancer?
The human body has many ways of letting you know something is wrong. It can send signals to tell you that you are hungry ...
OCT 06, 2020
Cannabis Sciences
Cannabis Use May Reduce Cancer Risk by 10%
OCT 06, 2020
Cannabis Use May Reduce Cancer Risk by 10%
A recent meta-analysis of 34 studies found that cannabis use may decrease one’s risk of developing certain kinds o ...
OCT 09, 2020
Cancer
Cloud technology cuts improve efficiency for cancer nurses
OCT 09, 2020
Cloud technology cuts improve efficiency for cancer nurses
In a new study reported in Clinical Cancer Informatics, an American Society of Clinical Oncology journal, medical provid ...
OCT 18, 2020
Cancer
Virus-mimicking drug attacks melanoma tumors
OCT 18, 2020
Virus-mimicking drug attacks melanoma tumors
Research published recently in the journal Science Translational Medicine from scientists at the UCLA Jonsson Compr ...
OCT 25, 2020
Cell & Molecular Biology
Revealing More About the Genetics of Ewing Sarcoma
OCT 25, 2020
Revealing More About the Genetics of Ewing Sarcoma
Ewing sarcoma is a rare kind of cancer that tends to impact young people and occurs in bones or the tissue around them. ...
Loading Comments...